Previous close | 0.1030 |
Open | 0.1010 |
Bid | 0.0966 x 3600 |
Ask | 0.0986 x 2800 |
Day's range | 0.0940 - 0.1032 |
52-week range | 0.0690 - 2.7900 |
Volume | |
Avg. volume | 18,869,030 |
Market cap | 6.824M |
Beta (5Y monthly) | 1.06 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.9100 |
Earnings date | 12 Aug 2024 - 16 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 8.00 |
ANN ARBOR, Mich., June 04, 2024--ENDRA Life Sciences Inc. (Nasdaq: NDRA) ("ENDRA" or the "Company"), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announced today that it has priced a public offering with gross proceeds to the Company expected to be approximately $8.0 million, before deducting placement agent fees and other estimated expenses payable by the Company. The offering is a best-efforts offering, with no minimum amount of securities required to be sold.
ANN ARBOR, Mich., May 20, 2024--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announced that it has completed what it considers to be a highly informative pre-submission meeting with the U.S. Food and Drug Administration (FDA) related to the clinical trial design of the TAEUS liver device in support of its U.S. De Novo filing.
Discover how ENDRA Life Sciences Inc navigates its financial landscape and strategic milestones amidst ongoing challenges.